SARS-CoV-2 Spike Antibody (CR3022)

ELISA: SARS-CoV-2 Spike Antibody (CR3022) [NBP2-90980] - Binding curve of SARS-CoV-2 Spike Antibody (CR3022) to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) (Native Antigen) at concentrations of 5 ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using SARS-CoV-2 Spike Antibody (CR3022). For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.

ELISA: SARS-CoV-2 Spike Antibody (CR3022) [NBP2-90980] - Binding curve of SARS-CoV-2 Spike Antibody (CR3022) to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (Native Antigen) at concentrations of 5 ug/ml. A 3-fold serial dilution from 125 ng/ml was performed using SARS-CoV-2 Spike Antibody (CR3022). For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.

• Reactivity: V
• Applications: ELISA, SPR
• Clone: CR3022
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Concentration: 1 mg/ml

SARS-CoV-2 Spike Antibody (CR3022) Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
• Specificity: This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). It binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020).
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Human
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Surface Plasmon Resonance
• Application Notes: The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 is available to assess its yet unknown role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).

Reactivity Notes

SARS-CoV, SARS-CoV-2

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for SARS-CoV-2 Spike Antibody (CR3022)

• 2019-nCoV S Protein
• 2019-nCoV Spike
• COVID-19 Spike
• Human coronavirus spike glycoprotein
• SARS-COV-2 S protein
• SARS-COV-2 Spike glycoprotein
• SARSCOV2 Spike protein
• Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
• Spike glycoprotein
• Spike

Background

Coronaviruses are positive-stranded RNA viruses, featuring the largest viral RNA genomes known to date (27-31 kb). Seven coronaviruses had been found to cause human infection including SARS-CoV-2/2019-nCoV resulting in a potentially fatal atypical pneumonia, named COVID-19. SARS-CoV-2 has 4 major structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), which share significant sequence homology with SARS-CoV. The spike protein in SARS-CoV-2 (1,273 aa) is a viral surface glycoprotein. Research on SARS-host protein interactions with SARS-CoV and SARS-CoV-2 viruses have shown that the viral spike (S) protein binds human ACE-2 located on the surface of mucosal cells, resulting in fusion of viral and cell membranes for viral entry. Viral entry also requires priming of the S protein by host cell proteases such as TMPRSS2, Cathepsin L or furin. The Coronavirus Spike precursor protein is processed into 2 distinct subunits with S1 (654 aa) housing the receptor binding domain (RBD) and S2 (588 aa or 458 a) facilitating membrane fusion.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P59594(Virus)